The social acceptability of psilocybin-assisted therapy for existential distress at the end of life is rather high in Canada. These findings may contribute to efforts to mobilise resources and improve access to this emerging therapy in palliative and end of life care settings.

A European consortium of 19 partners has been awarded €6,5 million by the European Union’s Horizon Europe programme to study psilocybin to treat psychological distress in people with progressive incurable illnesses requiring palliative care.

Proposed MAPS research projects for 2024 include MDMA-assisted Couples Therapy, Peace Building & Conflict Resolution, Marijuana for PTSD, and Psychedelics & the Legal System,

The FDA has 60 days to determine whether the NDA will be accepted for review and whether it will be a priority or standard review (six months or ten months, respectively).

We suggest that classic psychedelic-assisted therapies can be integrated into most mainstream evidence-based SUD treatments that are currently used in clinical settings, indicating broad compatibility of classic psychedelics with contemporary SUD treatment paradigms.

Tim Ferriss talks with Dr Willoughby Britton about her ground-breaking (and often unpopular) research highlighting potential dangers and worrying frequency of adverse effects associated with meditation practices (and similarly psychedelics).